Bioprocess International Europe 2026
Join us at Bioprocess International Europe to explore the path to more efficient bioprocessing, both upstream and downstream. Stop by booth #607, where our process development scientists and engineers will guide you through our recent innovations designed to enhance productivity, reduce costs, and improve the overall quality of bioprocessing.
Immerse yourself in Merck Booth #607
- Experience the AAViator™ Production Platform, a comprehensive solution that streamlines AAV production, delivering consistently high titers and superior quality for your gene therapy applications.
- Discover unparalleled performance with the CHOZN® Elite Cell Line, the next generation CHO host to boost your yield.
- Learn more how to enhance purification efficiency with chromatography membranes. Natrix® CH Chromatography Membrane is an innovative solution for efficient aggregate removal in monoclonal antibody (mAb) production. This single-use device utilizes advanced hydrogel membrane technology to achieve high binding capacity and rapid purification, enhancing productivity while minimizing buffer consumption.
- Come and see our new Mobius® iPUPSIT Filtration System and learn how to effectively mitigate risks in final sterile filtration.
- Finally, do not miss Millipore Express® Ace 0.2 µm filters, the most recent addition to our Millipore Express® membrane family, that deliver exceptional sterile filtration capacity and flux for a wide range of applications.
Attend Our Talks:
Enhancing Bioprocessing Efficiency with the Next-Generation CHOZN® Elite Platform
Dr. Sünje Fischer, Technical Application Consultant – Upstream Processing
The CHO CLD process is often time-consuming and resource-intensive. While advancements in vectors and robotics have improved throughput, they have not fully addressed the core productivity limits of traditional CHO hosts. We present the CHOZN® Elite cell line, a production-adapted CHO cell line that achieves high-yield clones using standard plasmids and media - without costly technologies - supported by our optimized fed-batch media solution. Clones from minipool and bulk pool workflows reached yields of up to 13 g/L and 5 g/L, respectively, with the latter achieved in just 80 days. This new host effectively accelerates CLD and enhances titers, resulting in significant cost savings.
Date: April 28, 2026
Time: 10:00 - 10:30
To 1000 L and beyond: Innovating AAV manufacturing for the next wave of gene therapies
Antoine Heron, PhD, Modality Consultant – Viral Vectors
In the rapidly evolving cell and gene therapy landscape, manufacturing efficiency remains a critical bottleneck for advancing AAV therapeutics from clinical trials to commercial production. Current AAV manufacturing processes face three key challenges: speed to market, maximization of performance, and commercial viability.
Innovation is required to enable successful commercialization of therapeutics to reach patients in need.
Many companies in industry are moving towards platform approaches to streamline process development and GMP manufacturing. This session will explore:
- Best-in-class performance in AAV production
- Process scale-up and manufacturing feasibility
- Process economic modelling
- Regulatory bottlenecks and solutions
Join this session to learn more about taking AAV production to new heights as the industry prepares for the next wave of gene therapies.
Date: April 29, 2026
Time: 02:45 - 03:15
Interested in scheduling time to meet with a member of our team? Contact your local sales representative.
Related Webinars
To continue reading please sign in or create an account.
Don't Have An Account?